GlassScriptPhysician profile
Kevin D Coyle
NPI 1891883765
$18,558.90
in general payments reported to CMS, 2019-2025
27 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $685 · 2021: $1,008 · 2022: $268 · 2023: $1,181 · 2024: $800 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16,931.23 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Collegium Pharmaceutical, INC. | $474.21 | 2019-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $183.55 | 2019-2023 | Ztlido |
| Saluda Medical Americas, INC. | $179.51 | 2023-2025 | Evoke Scs, Evoke |
| Kowa Pharmaceuticals America, INC. | $164.78 | 2023 | Seglentis |
| Si-Bone, INC. | $136.52 | 2019-2024 | |
| Biodelivery Sciences International, INC. | $71.32 | 2019-2021 | |
| Pfizer INC. | $51.54 | 2019-2021 | |
| Bioventus LLC | $33.95 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $33.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $29.16 | 2019 | |
| Sentynl Therapeutics, INC. | $26.60 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.79 | 2022 | |
| Eisai INC. | $19.05 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $16.43 | 2020-2021 | |
| Acelrx Pharmaceuticals, INC. | $16.41 | 2021 | |
| Abbvie INC. | $16.03 | 2023 | Botox |
| Amgen INC. | $15.84 | 2022 | |
| Virtus Pharmaceuticals LLC | $14.93 | 2021 | |
| Almatica Pharma LLC | $14.60 | 2021 | |
| Curonix LLC | $14.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Takeda Pharmaceuticals U.S.A., INC. | $13.49 | 2019 | |
| Lilly USA, LLC | $13.29 | 2021 | |
| Shionogi INC | $12.92 | 2019 | |
| Baudax Bio INC. | $12.63 | 2021 | |
| Medtronic USA, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Coyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.